Legal Disputes Between Pharmacies and SGK in Turkey

Introduction

Legal disputes between pharmacies and SGK in Turkey are among the most important financial and legal issues affecting pharmacy practice. Pharmacies in Turkey do not operate only under general pharmacy legislation. They also work within a public reimbursement system administered by the Social Security Institution, known in Turkish as Sosyal Güvenlik Kurumu or SGK. Since a significant part of medicine supply in Turkey is made to persons covered by SGK, disputes over prescription compliance, reimbursement deductions, MEDULA entries, medical reports, SUT conditions and protocol sanctions can directly affect a pharmacy’s cash flow and legal security.

These disputes are not simple accounting disagreements. They usually arise at the intersection of pharmacy law, administrative law, contract law, healthcare reimbursement rules, electronic prescription systems and public finance controls. A pharmacy may lawfully dispense a medicine under pharmacy law, but SGK may refuse payment if the prescription does not satisfy reimbursement conditions. Conversely, MEDULA may initially process a prescription, but SGK may later audit the claim and apply a deduction if it believes that the transaction violated SUT or protocol rules.

The current framework is shaped by the SGK–TEB pharmacy protocol, the Health Implementation Communiqué, known as SUT, the MEDULA pharmacy system, reimbursable medicine lists, SGK announcements and audit practice. SGK announced in March 2026 that it had signed the protocol concerning medicine supply from Turkish Pharmacists’ Association member pharmacies to persons covered by SGK; the announcement also stated that sales revenue brackets and prescription service fees were improved under the agreement. SGK also published a separate May 2026 announcement concerning the pharmacy medicine supply protocol and attached the relevant protocol document.

Legal Nature of Pharmacy–SGK Relationship

The legal relationship between pharmacies and SGK is not the same as an ordinary sale between a pharmacy and a patient. In SGK-covered medicine supply, the pharmacy provides medicine to the insured person, but payment is requested from SGK under reimbursement rules. This creates a mixed legal structure involving public reimbursement, contractual protocol obligations, electronic system processing and pharmacy professional duties.

The pharmacy’s right to payment depends on compliance with several layers of rules. First, the medicine must be lawfully dispensed under pharmacy law. Second, the patient must be covered and eligible. Third, the prescription must meet formal and substantive requirements. Fourth, the medicine must be reimbursable under the applicable list and conditions. Fifth, MEDULA entries must be accurate. Sixth, the pharmacy must comply with SGK–TEB protocol rules and invoice submission procedures.

For this reason, a pharmacy–SGK dispute often requires both legal and technical review. It is not enough to say that the medicine was delivered to the patient. The pharmacy must also prove that the prescription was reimbursable under the rules in force on the date of dispensing.

Main Legal Sources of Disputes

The most important legal sources in pharmacy–SGK disputes are the SGK–TEB protocol, SUT, MEDULA system rules, SGK announcements, reimbursable medicine lists and general principles of administrative and contract law. SGK continues to publish frequent updates regarding medicines whose costs are covered. For example, SGK published “Bedeli Ödenecek İlaçlar Listesinde Yapılan Düzenlemeler Hakkında Duyuru 2026/24” on 24 June 2026, with attached documents concerning the relevant list changes. SGK also published “Duyuru 2026/21” on 3 June 2026, again concerning changes to the reimbursable medicines list.

These updates matter because pharmacy disputes often depend on timing. A medicine may be reimbursable on one date but subject to a different condition, list status or payment rule on another date. Therefore, when reviewing a deduction or sanction, the first question should be: Which rule was in force on the prescription date and the dispensing date?

SGK announcements, SUT amendments and medicine list updates should be treated as primary evidence in reimbursement disputes. A pharmacy that objects to a deduction should not rely on general statements; it should identify the exact rule applicable at the relevant time.

Common Types of Legal Disputes Between Pharmacies and SGK

The most common disputes between pharmacies and SGK include reimbursement deductions, payment refusal, prescription audit findings, MEDULA entry errors, expired or invalid medical reports, diagnosis incompatibility, physician specialty problems, excessive quantity claims, repeated prescription issues, missing documentation, protocol sanctions, invoice return, delay in payment and disputes over patient contribution or price difference.

Some disputes are purely procedural. For example, a prescription may be medically and legally valid, but the pharmacy may have failed to submit a required report copy or entered an incorrect field in MEDULA. Other disputes are substantive. For example, SGK may allege that the medicine was not reimbursable for the diagnosis, that the report did not satisfy SUT conditions, or that the prescribing physician was not authorized.

There are also serious disputes involving suspected fraud, false prescriptions, fictitious patients, medicine not delivered to the patient, unlawful prescription collection, or repeated suspicious transactions. These matters may exceed ordinary reimbursement disputes and may create administrative, disciplinary and criminal risk.

Reimbursement Deductions

Reimbursement deductions are the most frequent source of pharmacy–SGK disputes. A deduction occurs when SGK does not pay all or part of a pharmacy’s claim, or later deducts amounts from payments, because it believes the prescription or submission violated reimbursement rules.

Typical deduction grounds include missing or invalid medical report, incorrect diagnosis code, wrong physician specialty, excess quantity, early refill, medicine outside reimbursable indication, non-compliant prescription date, wrong patient eligibility status, absence of required documents, inconsistency between MEDULA and physical documents, or non-compliance with protocol conditions.

From the pharmacy’s perspective, deductions can be financially severe. A single high-cost medicine deduction may create a major loss. Therefore, every deduction should be reviewed carefully. Pharmacies should determine whether SGK correctly applied the rule, whether the audit finding is factually accurate, whether the prescription date matters, whether MEDULA gave a misleading approval, and whether the deduction is proportionate.

MEDULA-Related Disputes

The MEDULA pharmacy system is central to SGK reimbursement. Pharmacies process prescriptions, patient eligibility, report information and reimbursement claims through MEDULA. However, MEDULA approval does not always eliminate legal risk. SGK may later argue that the pharmacy should have known the prescription did not meet SUT or protocol requirements.

This creates a common dispute: the pharmacy may claim that the system accepted the prescription, while SGK may argue that system acceptance is not a final legal guarantee. The outcome depends on the facts. If MEDULA displayed correct information and the pharmacy ignored an obvious inconsistency, SGK’s position may be stronger. If the system itself created ambiguity or accepted the transaction despite complete pharmacy compliance, the pharmacy may have a stronger objection.

A pharmacy should therefore preserve MEDULA screenshots, transaction numbers, electronic records and system warnings for high-risk prescriptions. In disputes, proof of what the system showed at the time of dispensing may be critical.

SUT-Related Disputes

SUT is one of the most important sources of pharmacy disputes. It determines reimbursement conditions for medicines, including diagnosis, medical report, physician specialty, dosage, treatment duration, age, laboratory values, previous treatment requirements and other criteria.

A pharmacy–SGK dispute may arise when SGK interprets a SUT provision strictly while the pharmacy argues that the prescription satisfied the rule. The dispute may concern whether a diagnosis is sufficient, whether a report phrase meets the condition, whether a specialist physician was required, whether the medicine was limited to certain patient groups, or whether the quantity exceeded permitted limits.

SUT disputes must be handled with legal precision. The pharmacy should cite the exact SUT provision in force at the relevant date, explain how the prescription and report satisfied that provision, and attach supporting medical and electronic documents. General statements such as “the patient needed the medicine” are usually not enough in reimbursement disputes.

Medical Report Disputes

Medical report issues are a frequent cause of deductions. SGK may reject reimbursement because the report was expired, incomplete, issued by an unauthorized provider, missing diagnosis, inconsistent with the prescribed medicine, not visible in the system, or not valid on the prescription date.

In practice, pharmacies often face difficult situations. The patient presents a prescription and report, MEDULA may allow processing, and the medicine may be delivered. Later, SGK may apply a deduction because the report did not satisfy a technical condition. The pharmacy then bears the financial risk unless it can show that the report was valid and compliant.

For this reason, pharmacies should apply enhanced review to report-dependent medicines. High-cost medicines, chronic disease medicines, biological products, oncology medicines, rare disease therapies and restricted medicines should not be dispensed without careful report verification.

Diagnosis and Indication Disputes

Many medicines are reimbursed only for specific diagnoses or indications. SGK may reject payment if the prescription diagnosis does not match the reimbursable indication or if the report does not clearly support the required clinical condition.

Diagnosis disputes can be legally complex. A physician may medically prescribe a medicine for a patient, but SGK reimbursement may be limited to certain indications. A pharmacy should not assume that medical necessity automatically equals reimbursement eligibility. The pharmacy must check whether the indication is covered under SUT and EK-4/A rules.

Where SGK applies a deduction, the pharmacy should examine whether the diagnosis code, report text, prescription content and SUT condition align. If the issue is merely terminology or coding, an objection may be possible. If the medicine was truly outside reimbursable scope, the deduction may be difficult to challenge.

Physician Specialty Disputes

Some medicines may be reimbursed only when prescribed by certain specialist physicians or based on reports issued by specified medical specialties. SGK may reject payment if the prescription was issued by a physician outside the required specialty or if the report was not prepared by the proper board or specialist.

This is a common problem because patients may receive prescriptions from family physicians, general practitioners or specialists after a report was issued by another department. The pharmacy must determine whether the prescription route complies with SGK rules. If a specialist prescription or report is required, the pharmacy should not rely only on the fact that a physician issued a prescription.

In disputes, the pharmacy should prove that the prescribing physician’s specialty was sufficient under the rule in force at the relevant time, or that the report allowed continuation prescriptions by other physicians.

Quantity, Dose and Repeat Prescription Disputes

SGK may apply deductions where it believes the quantity, dosage or repeat prescription timing exceeds reimbursement limits. These disputes may involve early refill, excess number of boxes, treatment duration limits, daily dose restrictions or repeated prescriptions before the permitted period.

The pharmacy’s defense should compare the prescription quantity with SUT rules, physician report, dosage instruction and MEDULA transaction. If the patient’s treatment required a higher quantity and the report permitted it, this should be documented. If the pharmacy supplied more than permitted because the patient requested it, SGK may reject reimbursement.

Quantity disputes are particularly important for expensive medicines. Pharmacies should implement internal controls for dose, duration and refill timing before dispensing high-cost prescriptions.

Reimbursable Medicine List Disputes

SGK’s reimbursable medicine list is dynamic. Medicines may be added, amended, activated or removed. SGK’s 2026 announcements show that the list of reimbursable medicines is updated repeatedly, including June 2026 announcements such as Duyuru 2026/21 and Duyuru 2026/24.

Disputes may arise where the pharmacy dispensed a medicine around the date of a list change. SGK may argue that the medicine was not reimbursable or was subject to a new condition. The pharmacy may argue that the previous rule applied or that the effective date of the change had not yet arrived.

In such cases, timing evidence is critical. The prescription date, dispensing date, MEDULA processing date, announcement date, effective date and invoice period should be compared carefully. A correct legal objection should focus on the rule applicable on the exact transaction date.

Protocol Sanctions

In addition to deductions based on SUT, pharmacies may face sanctions under the SGK–TEB protocol. Protocol sanctions may arise from document deficiencies, repeated errors, improper prescription processing, breach of special supply procedures, suspected irregularities, failure to comply with invoice rules or other contractual obligations.

SGK’s 2026 public announcement confirms that the SGK–TEB protocol is the framework for medicine supply from TEB-member pharmacies to SGK-covered persons. The protocol is therefore not merely an administrative document; it is the basis of the pharmacy’s contractual relationship with SGK for reimbursement.

When a protocol sanction is imposed, the pharmacy should review the exact protocol article, whether the conduct falls within the sanction definition, whether SGK complied with procedure, whether the sanction is proportionate, whether there is repetition, and whether corrective or mitigating evidence exists.

Invoice and Submission Disputes

Pharmacies must submit invoices and prescription documentation according to SGK procedures. Disputes may arise from late submission, missing documents, incorrect grouping, unreadable prescriptions, missing reports, inconsistent totals, incomplete electronic entries or failure to respond to SGK requests.

These disputes may seem technical, but they can have serious financial consequences. A pharmacy may have supplied the medicine correctly, but lose reimbursement because documentation was incomplete or late. Therefore, invoice submission should be treated as a legal process, not merely a clerical task.

Pharmacies should maintain monthly audit checklists. High-risk prescriptions should be checked before invoice submission. Supporting reports, system records, patient eligibility evidence and prescription documents should be preserved in an organized file.

Patient Contribution and Price Difference Disputes

Some disputes involve patients, pharmacies and SGK together. Patients may claim that the pharmacy charged an unlawful price difference or contribution, while the pharmacy may argue that SGK reimbursement did not cover the full amount. These disputes may involve reference pricing, equivalent medicine rules, contribution shares, non-covered items or system-calculated differences.

Pharmacies should be transparent in patient communication. If a price difference is collected, the legal and system basis should be explainable. Records should show what was reimbursed, what was collected from the patient and why. Poor communication can turn a lawful price difference into a complaint and investigation.

High-Cost Medicine Disputes

High-cost medicines create the most serious financial exposure. A deduction involving an oncology medicine, biological product, rare disease therapy or specialty medicine may cause a substantial loss. These medicines often require strict report, diagnosis, physician specialty, dosing and authorization conditions.

Before dispensing high-cost medicines, pharmacies should apply a separate legal and reimbursement review. The responsible pharmacist should verify SUT conditions, report validity, patient eligibility, MEDULA status, diagnosis, quantity, physician specialty and any special protocol provisions. The pharmacy should preserve all supporting documents.

If SGK later applies a deduction, the objection should be detailed and evidence-based. High-cost medicine disputes often justify professional legal review because the financial stakes are significant.

Suspected Fraud and Serious Irregularity Disputes

Some disputes go beyond ordinary deduction. SGK may allege fictitious prescriptions, false reports, medicine not delivered to the patient, repeated suspicious prescriptions, collusion with physicians, prescription collection, unlawful referral or fraudulent reimbursement.

These matters can create serious legal consequences. They may lead to protocol sanctions, administrative investigation, professional disciplinary proceedings, criminal complaint and civil recovery claims. Pharmacies should treat such allegations urgently.

The defense must be document-heavy. The pharmacy should gather prescriptions, patient delivery evidence, MEDULA records, stock and İTS records, invoice documents, camera records if lawfully available, patient communications and staff explanations. A vague denial is not enough where SGK alleges systematic irregularity.

Burden of Proof and Evidence

In pharmacy–SGK disputes, evidence is decisive. The pharmacy should be able to prove compliance with the applicable rule. Important evidence includes prescription copies, e-prescription records, MEDULA transaction data, medical reports, diagnosis codes, physician information, patient eligibility records, invoice submission files, SGK announcements, SUT provisions, protocol articles, İTS records and internal pharmacy notes.

A pharmacy should not wait for a dispute to collect evidence. Evidence should be preserved during ordinary operations. This is especially important because disputes may arise months after the prescription was dispensed. If the pharmacy cannot reconstruct the transaction, it may be difficult to object effectively.

Internal Objection Process

When SGK applies a deduction or sanction, the pharmacy should first review the internal objection route provided under the applicable protocol and SGK procedure. The pharmacy should identify the deadline, prepare a written objection, attach evidence and explain why the deduction or sanction is unlawful or incorrect.

An effective objection should be structured. It should identify the prescription, transaction date, deduction reason, applicable rule, factual evidence and legal conclusion. The pharmacy should avoid emotional language and focus on proof. If SGK made a factual mistake, the evidence should show the mistake clearly. If the dispute concerns legal interpretation, the objection should explain why the pharmacy’s interpretation is correct.

Judicial Remedies

If internal objections do not resolve the dispute, judicial remedies may be considered. The correct court, procedure and legal basis may depend on the nature of the dispute, the protocol relationship, SGK’s action, amount, sanction type and whether the dispute is treated as contractual, administrative or reimbursement-related.

Pharmacies should be careful with limitation periods and deadlines. Delay may cause loss of rights. In some cases, it may be necessary to seek cancellation of a sanction, recovery of withheld amounts, declaratory relief or damages. The litigation strategy should be tailored to the specific SGK action.

A strong court file should include not only legal arguments but also a clear technical explanation of the prescription process, MEDULA entry, SUT condition and pharmacy workflow. Judges may not be familiar with pharmacy reimbursement mechanics; therefore, the petition must explain the system clearly.

Preventive Compliance for Pharmacies

The best way to handle SGK disputes is to prevent them. Pharmacies should establish a compliance system for SGK-covered prescriptions. This system should include staff training, report verification, high-cost medicine review, MEDULA record preservation, monthly invoice audit, SUT update monitoring, protocol article tracking and internal documentation.

SGK list changes and announcements must be monitored continuously. The fact that SGK published reimbursable medicine list updates on 3 June 2026 and 24 June 2026 shows how frequently reimbursement conditions can change. A pharmacy that does not follow these updates may process prescriptions under outdated rules.

High-risk categories should be reviewed by the responsible pharmacist personally. These include oncology drugs, biological products, rare disease medicines, controlled medicines, expensive chronic therapies, imported medicines, report-dependent medicines and prescriptions near rule-change dates.

Practical Checklist for SGK Dispute Prevention

A pharmacy should apply a clear checklist before dispensing SGK-covered medicines. First, confirm patient eligibility. Second, check whether the medicine is reimbursable on the transaction date. Third, review SUT conditions. Fourth, verify the medical report. Fifth, confirm diagnosis and physician specialty. Sixth, check dose, quantity and repeat prescription timing. Seventh, confirm MEDULA entries. Eighth, preserve system records. Ninth, verify patient contribution or price difference. Tenth, complete invoice documentation.

For high-cost medicines, a second review should be conducted. The responsible pharmacist should check the report, prescription, MEDULA screen and SUT provision before delivery. Any ambiguity should be resolved before the medicine is supplied.

Practical Checklist for Objecting to SGK Deductions

When a deduction is received, the pharmacy should follow a second checklist. First, obtain the SGK deduction notice and reason. Second, identify the prescription and transaction date. Third, retrieve the prescription, report and MEDULA records. Fourth, identify the SUT and protocol rule in force on that date. Fifth, compare SGK’s allegation with the documents. Sixth, determine whether the issue is factual, legal or procedural. Seventh, prepare a written objection with attachments. Eighth, file within deadline. Ninth, monitor the result. Tenth, consider litigation if the objection is rejected and the amount or principle justifies it.

This structured approach prevents weak objections. A strong objection is not a general complaint; it is an evidence-based legal response.

Role of Legal Counsel in Pharmacy–SGK Disputes

Legal counsel can be important in SGK disputes, especially where the amount is high, the sanction affects the pharmacy’s protocol status, fraud is alleged, repeated deductions exist, or the dispute concerns interpretation of SUT or protocol provisions.

A lawyer should review both the legal and technical side. The petition or objection must explain pharmacy workflow, MEDULA processing, report rules, SUT conditions and SGK’s error. It should also address procedural fairness, proportionality, acquired rights, legitimate expectation, effective date of rule changes and evidentiary burden.

In serious cases, counsel should also consider whether the same facts may create criminal, disciplinary or administrative consequences. A statement made casually in an SGK objection may later affect another proceeding. Therefore, the defense strategy should be coordinated.

Frequently Asked Questions

What are the most common legal disputes between pharmacies and SGK in Turkey?

The most common disputes involve reimbursement deductions, invalid medical reports, SUT non-compliance, MEDULA entry problems, physician specialty issues, diagnosis mismatch, high-cost medicine deductions, protocol sanctions and invoice documentation deficiencies.

Does MEDULA approval guarantee SGK payment?

No. MEDULA approval is important, but SGK may later audit the prescription and apply deductions if it concludes that SUT, protocol or documentation rules were not satisfied.

Why do reimbursable medicine list updates matter?

SGK frequently updates the list of medicines whose costs are covered. For example, SGK published list update announcements on 3 June 2026 and 24 June 2026. These updates may affect whether a medicine is reimbursable and under what conditions.

What should a pharmacy do after an SGK deduction?

The pharmacy should identify the deduction reason, retrieve the prescription file, compare the transaction with the SUT and protocol rules in force on the dispensing date, and submit a timely objection with supporting documents.

Can SGK disputes lead to criminal risk?

Yes, if the dispute involves suspected false prescriptions, fictitious patients, fraudulent reimbursement, medicine not delivered to patients, unlawful prescription referral or similar serious allegations. Ordinary technical deductions do not automatically mean criminal liability, but serious irregularity claims should be handled carefully.

Conclusion

Legal disputes between pharmacies and SGK in Turkey are a major part of modern pharmacy practice. These disputes usually arise from reimbursement deductions, SUT interpretation, MEDULA records, medical report validity, prescription conditions, reimbursable medicine list changes, SGK–TEB protocol sanctions and audit findings.

The key legal principle is that lawful dispensing and SGK reimbursement are not identical. A pharmacy may supply a medicine lawfully under pharmacy law, but SGK may refuse reimbursement if the transaction does not satisfy SUT, EK-4/A, MEDULA or protocol conditions. Therefore, pharmacies must operate with a dual compliance system: pharmacy law compliance and SGK reimbursement compliance.

The SGK–TEB protocol signed in 2026 remains a central framework for medicine supply from TEB-member pharmacies to SGK-covered persons. SGK’s continuing 2026 announcements on reimbursable medicine list changes show that reimbursement rules are dynamic and must be monitored closely.

For pharmacies, the safest strategy is preventive compliance. Every SGK-covered prescription should be checked for patient eligibility, report validity, diagnosis, physician specialty, quantity, MEDULA consistency, reimbursement list status and supporting documentation. High-cost medicines should receive enhanced review before delivery.

When a dispute arises, the pharmacy should act quickly, preserve evidence, identify the applicable rule, file a structured objection and consider judicial remedies where necessary. In SGK disputes, documentation is often stronger than argument. A pharmacy that keeps accurate records, monitors rule changes and responds professionally to deductions can significantly reduce financial risk and protect its legal position.